Metabesity and urological cancers

Area of Science:

• Endocrinology
• Oncology
• Public Health

Background:

• Metabolic syndrome is a growing global health concern with significant cardiovascular implications.
• Emerging evidence highlights metabolic syndrome's broader impact on human health, including its association with malignancy.
• The concept of 'metabesity' has been introduced to encompass the comprehensive health risks posed by metabolic dysfunction.

Purpose of the Study:

• To review and synthesize current knowledge on metabesity.
• To examine the relationship between metabesity and urological cancers.
• To provide an overview of the available information linking metabolic dysfunction to urological malignancies.

Main Methods:

• Literature review of existing studies on metabolic syndrome, metabesity, and urological cancers.
• Synthesis of data from epidemiological and clinical research.
• Analysis of the mechanisms potentially linking metabolic dysfunction to cancer development.

Main Results:

• Metabolic syndrome, redefined as metabesity, is increasingly recognized as a risk factor for various cancers.
• Specific associations between metabesity and increased risk of urological cancers (e.g., prostate, bladder, kidney) are being investigated.
• Metabesity contributes to a pro-inflammatory and pro-oxidative environment that can promote cancer initiation and progression.

Conclusions:

• Metabesity represents a significant and complex health challenge with implications for cancer risk.
• Understanding the link between metabesity and urological cancers is crucial for developing effective prevention and treatment strategies.
• Further research is warranted to elucidate the precise biological pathways and clinical impact of metabesity on urological malignancies.